Abstract
Introduction A number of extra fellowships after traditional hematology oncology training have started in recent years, including training in lymphoma, myeloma, bone marrow transplantation, and leukemia. The benefit of this additional training is disputed.
Methods and Materials We sought to quantify, from publicly reported data, what percentage of trainees either performed the extra year at the same location as they performed their fellowship– raising the question why they did not gain this training during the regular fellowship years– and what fraction stayed on at the same institution–raising the question of why the training was not performed on the job. Google and LinkedIn searches were performed to assemble the dataset.
Results We examined 6 programs that made their graduate information public. We found 30% (17/56) of fellows either trained at the same institution or remained at the same institution as their extra fellowship.
Conclusion Nearly 1 in 3 trainees that forgo an extra year do so in a context where they had opportunity to work at that center before or afterwards, raising the question as to whether the extra year was needed or could have been built into existing professional obligations.
Competing Interest Statement
(Research funding) Arnold Ventures (Royalties) Johns Hopkins Press, Medscape, and MedPage (Honoraria) Grand Rounds/lectures from universities, medical centers, non-profits, and professional societies. (Consulting) UnitedHealthcare and OptumRX. (Other) Plenary Session podcast has Patreon backers, YouTube, and Substack.
Funding Statement
This study was funded by Arnold Ventures.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This study was funded by Arnold Ventures
Conflict(s) of interest: (Research funding) Arnold Ventures (Royalties) Johns Hopkins Press, Medscape, and MedPage (Honoraria) Grand Rounds/lectures from universities, medical centers, non-profits, and professional societies. (Consulting) UnitedHealthcare and OptumRX. (Other) Plenary Session podcast has Patreon backers, YouTube, and Substack.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
